Janssen Search
Search results
RYBREVANT®▼ (amivantamab) in combination with chemotherapy is the first therapy approved by the European Commission for the first-line treatment of patients with advanced non-small cell lung cancer with activating EGFR exon 20 insertion mutations
Jun 28, 2024 Approval is supported by the Phase 3 PAPILLON study, which showed amivantamab plus chemotherapy significantly reduced the risk of disease progression or death by 60 percent compared to chemotherapy alone 1 BEERSE, BELGIUM (28 June 2024) – ...
Janssen to Highlight Scientific Advances and Commitment to Transform Cancer Care at ASCO and EHA with More than 90 Presentations Showcasing Robust, Differentiated Portfolio and Pipeline in Hematologic Malignancies and Solid Tumors
May 18, 2023 United States Launch of Multidisciplinary Council of Experts Call-to-Action During EHA Demonstrates Continued Commitment to Innovation in Multiple Myeloma RARITAN, N.J., May 18, 2023 — The Janssen Pharmaceutical Companies of Johnson & ...
European Commission approves RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the treatment of adult patients with advanced EGFR-mutated non-small cell lung cancer after failure of prior therapy
Aug 27, 2024 Belgium Patients with EGFR ex19del or EGFR L858R mutations, the most common EGFR mutations in NSCLC, have until now faced a poor prognosis and limited treatment options after disease progression on an EGFR TKI [1], [2], [3], [4] Amivantamab ...
Janssen Submits Application to the European Medicines Agency for RYBREVANT®▼ (amivantamab) in Combination with Chemotherapy for the First-Line Treatment of Adult Patients with Advanced Non-Small Cell Lung Cancer with Activating EGFR Exon20ins Mutations
Oct 06, 2023 Belgium Type II Extension of Indication Application is supported by data from PAPILLON, the first randomised Phase 3 study to read out in patients with NSCLC with EGFR exon 20 insertion mutations [i] BEERSE, BELGIUM, 6 October, 2023 – The ...
Janssen Submits Type II Extension of Indication Application to the European Medicines Agency Seeking Approval of RYBREVANT®▼ (amivantamab), in combination with Lazertinib, for First-Line Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer
Feb 08, 2024 Belgium The submission is supported by data from the Phase 3 MARIPOSA study, showing statistically significant and clinically meaningful improvement in progression-free survival in patients with EGFR-mutated advanced NSCLC treated with ...
CHMP recommends RYBREVANT®▼ (amivantamab) in combination with chemotherapy for the treatment of adult patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC) after failure of prior therapy
Jul 26, 2024 Patients with EGFR ex19del or EGFR L858R mutations, the most common EGFR mutations in NSCLC, currently face a poor prognosis and limited treatment options after disease progression on osimertinib 1, 2, 3, 4 In the MARIPOSA-2 study, ...
Janssen Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of Lazertinib, in combination with RYBREVANT®▼ (amivantamab), for the First-Line Treatment of Patients with EGFR-Mutated Non-Small Cell Lung Cancer
Dec 21, 2023 Belgium The submission is supported by data from the Phase 3 MARIPOSA study, which featured in a Late-Breaking Presidential Symposium session at the 2023 ESMO Congress [1] Lazertinib is a highly selective, central nervous system-penetrant, ...
Janssen Submits Application to the European Medicines Agency for RYBREVANT®▼ (amivantamab) in Combination with Chemotherapy for the Treatment of Adult Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer After Failure of Prior Therapy
Nov 27, 2023 Belgium The submission is supported by data from the Phase 3 MARIPOSA-2 study featured in a Late-Breaking Presidential Symposium session at the 2023 ESMO Congress and simultaneously published in Annals of Oncology [1], [2] Amivantamab plus ...